Nuveen LLC Invests $579,000 in Compass Therapeutics, Inc. $CMPX

Key Points

• Nuveen LLC acquired 304,504 shares of Compass Therapeutics, Inc. valued at around $579,000, representing approximately 0.22% ownership in the company, according to their recent SEC filing.
• Compass Therapeutics reported a loss of ($0.14) earnings per share, which was below the consensus estimate of ($0.13), and analysts expect a projected loss of -$0.36 earnings per share for the current fiscal year.
• Analysts maintain a consensus "Buy" rating on Compass Therapeutics, with price targets ranging from $9.00 to $32.00, and an average price target of $12.89.

Nuveen LLC purchased a new position in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 304,504 shares of the company's stock, valued at approximately $579,000. Nuveen LLC owned about 0.22% of Compass Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its position in Compass Therapeutics by 298.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock worth $25,000 after buying an additional 12,917 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in Compass Therapeutics during the fourth quarter worth about $27,000. Mariner LLC purchased a new position in Compass Therapeutics during the fourth quarter worth about $30,000. Squarepoint Ops LLC acquired a new stake in Compass Therapeutics in the fourth quarter valued at approximately $35,000. Finally, ProShare Advisors LLC raised its holdings in Compass Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock worth $42,000 after purchasing an additional 9,451 shares in the last quarter. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Price Performance

Shares of NASDAQ:CMPX traded up $0.05 during trading on Monday, reaching $3.49. 622,808 shares of the stock were exchanged, compared to its average volume of 1,377,300. Compass Therapeutics, Inc. has a 1-year low of $1.27 and a 1-year high of $4.08. The firm has a market cap of $481.91 million, a price-to-earnings ratio of -7.74 and a beta of 1.50. The stock has a fifty day moving average of $3.01 and a two-hundred day moving average of $2.47.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). Sell-side analysts forecast that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Guggenheim upped their target price on shares of Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Tuesday, August 12th. Raymond James Financial raised shares of Compass Therapeutics to an "outperform" rating and set a $9.00 price target for the company in a report on Tuesday, July 1st. Finally, D. Boral Capital restated a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating and nine have issued a Buy rating to the stock. According to MarketBeat, Compass Therapeutics presently has an average rating of "Buy" and a consensus target price of $12.89.

Compass Therapeutics Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.